CJC-1295 (without DAC)

Technical Specifications

• Product: CJC-1295 (without DAC)
• Quantity: 2 mg label claim
• Research Classification: Short-Acting GHRH Analog
• Compound Type: Modified GHRH Peptide Analog
• Primary Research Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)
• COA-Reported CAS Number: 863288-34-0
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: Approximately 3367.9 g/mol
• Peptide Length: 29 amino acids
• Chromatographic Purity: 99.31%
• Identity: CJC-1295 confirmed by HPLC-UV-MS
• Measured Content: 2.04 mg
• Percent of Label: 101.9%
• Analysis Method: HPLC-UV-MS
• Laboratory: Krause Analytical
• Lab Number: 200510
• Project: 145030
• Report Issued: February 9, 2026

The purity, identity, measured content, and CAS number above come directly from the independent laboratory report for the submitted OPTMZ sample.

PubChem lists CJC-1295 without DAC as C₁₅₂H₂₅₂N₄₄O₄₂.

Analytical & Testing

Each tested batch of CJC-1295 (without DAC) undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.

For the submitted OPTMZ Peptides sample, Krause Analytical reported:

• Chromatographic Purity: 99.31%
• Identity: CJC-1295 — Confirmed
• Measured Content: 2.04 mg
• Label Claim: 2 mg
• Percent of Label: 101.9%
• Testing Method: HPLC-UV-MS
• CAS Number: 863288-34-0
• Lab Number: 200510
• Project: 145030

The laboratory states that the data presented are from the analyzed sample and meet its internal quality-assurance criteria unless otherwise flagged.

Page 2 of the report includes both the chromatogram and a direct mass-spectrum/reference-spectrum comparison for the CJC-1295 sample.

Note: This COA does not report endotoxin testing, so I would not state that this specific lot was endotoxin tested.

Handling & Storage

CJC-1295 (without DAC) should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.

Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.

Research Context

CJC-1295 (without DAC) is investigated primarily as a GHRH analog for experimental study of the growth hormone-releasing hormone receptor and downstream endocrine signaling.

Research areas include:

• GHRH receptor signaling
• Growth hormone secretion pathways
• IGF-1-associated signaling
• Pituitary biology
• Somatotroph signaling
• Endocrine pathway research
• GHRH analog structure-function studies
• Peptide pharmacology
• Modified GRF research
• Growth hormone pulse signaling

The non-DAC form is structurally related to Modified GRF (1-29), a stabilized GHRH-derived peptide designed to retain GHRH receptor activity while avoiding the albumin-binding DAC modification.

This distinction is important because much of the published human literature on CJC-1295 specifically concerns the DAC-containing long-acting form, not necessarily the non-DAC peptide. Published CJC-1295 studies therefore should not automatically be used to make pharmacokinetic claims about CJC-1295 without DAC.

Research Application Scope

CJC-1295 (without DAC) is relevant to controlled laboratory investigations involving GHRH receptor biology, pituitary signaling, growth-hormone-associated pathways, endocrine cell signaling, and peptide structure-function relationships.

Because it lacks the Drug Affinity Complex, it is especially relevant to comparative research examining DAC versus non-DAC GHRH analogs and how albumin-binding modifications alter peptide persistence and pharmacology.

Use Statement

For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.

Disclaimer

All products currently listed on this site are for research purposes ONLY.